{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T04:30:29Z","timestamp":1722313829507},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Combination therapy with hydroxychloroquine and darunavir\/ritonavir or lopinavir\/ritonavir has been suggested as an approach to improve the outcome of patients with moderate\/severe COVID-19 infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To examine the safety of combination therapy with hydroxychloroquine and darunavir\/ritonavir or lopinavir\/ritonavir.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an observational cohort study of patients hospitalized for COVID-19 pneumonia treated with hydroxychloroquine and darunavir\/ritonavir or lopinavir\/ritonavir. Clinical evaluations, electrocardiograms and the pharmacokinetics of hydroxychloroquine, darunavir and lopinavir were examined according to clinical practice and guidelines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twenty-one patients received hydroxychloroquine with lopinavir\/ritonavir (median age 68\u2009years; 10 males) and 25 received hydroxychloroquine with darunavir\/ritonavir (median age 71\u2009years; 15 males). During treatment, eight patients (17.4%) developed ECG abnormalities. Ten patients discontinued treatment, including seven for ECG abnormalities a median of 5 (range 2\u20136) days after starting treatment. All ECG abnormalities reversed 1\u20132\u2009days after interrupting treatment. Four patients died within 14\u2009days. ECG abnormalities were significantly associated with age over 70\u2009years, coexisting conditions (such as hypertension, chronic cardiovascular disease and kidney failure) and initial potential drug interactions, but not with the hydroxychloroquine concentration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Of the patients with COVID-19 who received hydroxychloroquine with lopinavir or darunavir, 17% had ECG abnormalities, mainly related to age or in those with a history of cardiovascular disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa441","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T20:15:08Z","timestamp":1605557708000},"page":"482-486","source":"Crossref","is-referenced-by-count":8,"title":["Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection"],"prefix":"10.1093","volume":"76","author":[{"given":"Etienne","family":"Meriglier","sequence":"first","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"},{"name":"Univ. Bordeaux, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Rivoisy","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mojgan","family":"Hessamfar","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle","family":"Bernard","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Aureau","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Lapoirie","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"},{"name":"Univ. Bordeaux, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Contis","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Sacher","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, F-33000 Bordeaux, France"},{"name":"IHU LIRYC, Universit\u00e9 de Bordeaux, CHU de Bordeaux, Service de cardiologie, H\u00f4pital Haut-L\u00e9v\u00eaque, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Sacristan","sequence":"additional","affiliation":[{"name":"Univ. Bordeaux, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marin","family":"Lahouati","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de pharmacie clinique des m\u00e9dicaments, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Pedeboscq","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de pharmacie clinique des m\u00e9dicaments, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Vandenhende","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"},{"name":"Univ. Bordeaux, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Bouchet","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Laboratoire de pharmacologie \u2013 toxicologie, H\u00f4pital Pellegrin, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Bonnet","sequence":"additional","affiliation":[{"name":"CHU de Bordeaux, Service de m\u00e9decine interne et maladies infectieuses, H\u00f4pital Saint-Andr\u00e9, F-33000 Bordeaux, France"},{"name":"Univ. Bordeaux, F-33000 Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,21]]},"reference":[{"key":"2021012006031465200_dkaa441-B1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021012006031465200_dkaa441-B2","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"2021012006031465200_dkaa441-B3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/M20-1223","article-title":"A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19","volume":"172","author":"Kim","year":"2020","journal-title":"Ann Intern Med"},{"key":"2021012006031465200_dkaa441-B4","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"2021012006031465200_dkaa441-B5","doi-asserted-by":"crossref","first-page":"m1849","DOI":"10.1136\/bmj.m1849","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"key":"2021012006031465200_dkaa441-B6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/2048872620922784","article-title":"Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol","volume":"9","author":"Naksuk","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2021012006031465200_dkaa441-B7","first-page":"545","article-title":"Electrocardiogram abnormalities related to anti-malarials in systemic lupus erythematosus","volume":"36","author":"McGhie","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"2021012006031465200_dkaa441-B8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"2021012006031465200_dkaa441-B9","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"2021012006031465200_dkaa441-B10","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","article-title":"SARS-CoV-2: recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus","volume":"27","author":"Costanzo","year":"2020","journal-title":"Curr Med Chem"},{"key":"2021012006031465200_dkaa441-B11","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/00126334-200408150-00006","article-title":"Coadministration of lopinavir\/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction","volume":"36","author":"Lim","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021012006031465200_dkaa441-B12","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/S1473-3099(20)30312-1","article-title":"Plea for multitargeted interventions for severe COVID-19","volume":"20","author":"Gaborit","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2021012006031465200_dkaa441-B13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.acvd.2020.04.003","article-title":"Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection","volume":"113","author":"Sacher","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"2021012006031465200_dkaa441-B14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/acr.22370","article-title":"Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort","volume":"67","author":"Bourr\u00e9-Tessier","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2021012006031465200_dkaa441-B15","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1310\/hct0906-418","article-title":"Pharmacokinetics, efficacy, and safety of darunavir\/ritonavir 800\/100 mg once-daily in treatment-na\u00efve and -experienced patients","volume":"9","author":"Boffito","year":"2008","journal-title":"HIV Clin Trials"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/2\/482\/35925272\/dkaa441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/2\/482\/35925272\/dkaa441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T14:09:26Z","timestamp":1611151766000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/2\/482\/5998282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,21]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,11,21]]},"published-print":{"date-parts":[[2021,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa441","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2]]},"published":{"date-parts":[[2020,11,21]]}}}